Adipocyte Na, K-ATPase Signaling Attenuates Experimental Uremic Cardiomyopathy

Area of Science:

• Cardiovascular Biology
• Metabolic Diseases
• Renal Medicine

Background:

• Oxidative stress and altered intracellular signaling in adipocytes contribute to obesity comorbidities and cardiovascular issues.
• Dysregulation of sodium-potassium adenosine triphosphatase (Na, K-ATPase) signaling is linked to systemic inflammation and metabolic disturbances.
• Adipocyte Na, K-ATPase signaling's role in uremic cardiomyopathy requires further investigation.

Purpose of the Study:

• To investigate the specific role of adipocyte Na, K-ATPase signaling in mitigating experimental uremic cardiomyopathy.
• To determine if targeting adipocyte Na, K-ATPase signaling can prevent or reverse cardiac and metabolic alterations in a mouse model.

Main Methods:

• Experimental uremic cardiomyopathy was induced in mice via partial nephrectomy (PNx).
• Adipocyte-specific expression of NaKtide, a Na, K-ATPase inhibitor, was achieved using a lentivirus with an adiponectin promoter.
• Disease phenotype, adipocyte molecular changes, systemic inflammation, and oxidative stress were assessed, with and without a Western diet.

Main Results:

• Partial nephrectomy induced cardiomyopathy, anemia, adipocyte dysfunction, inflammation, and oxidative stress within 4 weeks.
• These pathological changes were exacerbated by a Western diet.
• Adipocyte-specific NaKtide expression significantly prevented or ameliorated these PNx-induced alterations, while skeletal muscle-specific expression did not.
• Adipocyte dysfunction and uremic cardiomyopathy were significantly improved by adipocyte-specific NaKtide expression.

Conclusions:

• Adipocyte Na, K-ATPase signaling plays a pivotal role in the development and progression of uremic cardiomyopathy.
• The oxidative environment within adipocytes is critical in driving uremic cardiomyopathy in the context of partial nephrectomy.
• Targeting adipocyte Na, K-ATPase signaling represents a potential therapeutic strategy for chronic renal failure complications.